Thyroid Cancer Survival Rates: What the Numbers Mean and Why Most Are Better Than You May Think
Written by John P. Sabra, MD FACS
Updated September 2026
Educational only. This article is not medical advice. Always consult your physician about your individual situation.
Survival rate is understandably the first thing most patients search for after a cancer diagnosis. For thyroid cancer, what the numbers actually show is one of the most underappreciated facts in oncology: differentiated thyroid cancer has a five-year survival rate that exceeds 98% in localized disease and remains above 75% even when distant spread is present. The 2% who do not survive five years are not random.
Survival statistics are aggregates of people in a population group. They describe what has happened to large groups of patients diagnosed with the same disease over the same time period. They do not predict any one patient’s outcome with precision. Your actual prognosis depends on the specific type of thyroid cancer, the stage at diagnosis, your age and overall health, and the quality of the treatment you receive. A 98% survival rate for localized papillary thyroid cancer does not mean every patient has a 98% chance. It means that out of 100 patients with that diagnosis, 98 are alive five years later. For patients with average risk factors and access to good care, the individual probability is often well above 98%. For patients with high-risk features, it can be lower.
Survival Rates by Thyroid Cancer Type
Thyroid cancer is not a single disease, and the survival statistics differ dramatically depending on which type you have. The most useful numbers come from the SEER program (Surveillance, Epidemiology, and End Results), which tracks cancer outcomes across the United States.
| Cancer Type | Localized | Regional | Distant |
|---|---|---|---|
| Papillary | Greater than 99% | Approximately 99% | Approximately 75% |
| Follicular | Greater than 99% | Approximately 96% | Approximately 65% |
| Medullary | Approximately 99% | Approximately 91% | Approximately 41% |
| Anaplastic | Approximately 31% | Approximately 12% | Approximately 4% |
Numbers in this table represent five-year relative survival. Relative survival adjusts for deaths from causes other than cancer and is the standard statistic used to describe cancer-specific outcome. The differences between cancer types are striking, and they reflect fundamentally different biology, not differences in care.
⚕ Clinical note: The published survival statistics for thyroid cancer are based on patients diagnosed up to 10 or 15 years ago, treated with the standards of that time. For some cancers (particularly anaplastic), outcomes today are meaningfully better than the historical numbers because of new targeted therapies. For others, the numbers have not changed much because they were already excellent. Survival data published more recently is generally more accurate.
What “Localized,” “Regional,” and “Distant” Mean
-
Localized: The cancer is confined to the thyroid gland. No lymph node involvement, no distant spread. The majority of newly diagnosed thyroid cancers fall in this category.
-
Regional: The cancer has spread to nearby lymph nodes in the neck or to immediately adjacent structures. Common in papillary thyroid cancer, less common in follicular cancer.
-
Distant: The cancer has spread to distant sites such as lungs, bones, or other organs. Uncommon at the time of initial diagnosis for differentiated thyroid cancer.
The category that applies to you is determined by the staging workup: surgical pathology, neck ultrasound, and in some cases additional imaging such as CT, MRI, or a whole-body iodine scan.
Why Age Matters So Much
For differentiated thyroid cancers (papillary, follicular, Hurthle cell), age at diagnosis is one of the strongest prognostic factors. Patients diagnosed before age 55 have substantially better long-term survival than patients diagnosed at older ages, even after adjusting for tumor size and extent. This is why the AJCC staging system uses age 55 as a cutoff for higher stage classification.
The biological reasons for this age difference are not fully understood. Cancer cells in older patients appear to behave slightly more aggressively, the body’s response to cancer differs with age, and the cumulative effects of treatment differ. The clinical implication is straightforward: a 30-year-old and a 70-year-old with identical-appearing papillary thyroid cancers may have meaningfully different prognoses.
Why Survival Is High but Recurrence Is Not Zero
Survival statistics and recurrence statistics are different. You can have a recurrence of papillary thyroid cancer and still have an excellent long-term survival. Recurrence in differentiated thyroid cancer is most often detected in neck lymph nodes during routine surveillance, is usually treatable with additional surgery or radioactive iodine, and does not usually translate into a life-threatening event.
This is one of the reasons structured surveillance after initial treatment is important even when survival statistics are very high. Catching a recurrence early gives the best chance of an additional treatment being curative.
⚕ Clinical note: The survival numbers most patients see online are usually 5-year relative survival rates. For differentiated thyroid cancer, 10-year and 20-year survival statistics are also published and remain very high. Papillary thyroid cancer has a 20-year survival rate above 90% for most stages. This is one of the few cancers where it is reasonable to think in decades rather than years.
What Predicts an Outcome Above the Average
-
Younger age at diagnosis: Patients under 55 have systematically better outcomes.
-
Smaller tumor at diagnosis: Tumors under 2 cm have lower recurrence and better survival than larger tumors.
-
No lymph node involvement: Absence of nodal spread is favorable.
-
Standard histologic type: Classic papillary thyroid cancer has better outcomes than aggressive variants such as tall cell, columnar cell, or hobnail variant papillary cancer.
-
Treatment at a high-volume center: Outcomes correlate with surgeon and center experience, particularly for cancers requiring complex neck surgery.
The Bottom Line
For most patients with thyroid cancer, survival rates are among the highest in oncology. Papillary thyroid cancer has a five-year survival rate above 98% for the great majority of patients. Follicular and medullary cancers have favorable outcomes when caught at earlier stages. Anaplastic thyroid cancer remains the exception, and survival statistics for that diagnosis must be read differently. The numbers are statistics for groups, not predictions for individuals, but they give an accurate sense of the favorable outlook for most thyroid cancer diagnoses.
If you have just been diagnosed, ask your team for your specific risk category and what survival statistics apply to that category rather than averaging across all thyroid cancer.
This article is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. Individual patient circumstances and clinical judgment determine the appropriate evaluation and management for every patient.
More from the Thyroid Cancer series
Ready to Talk to a Specialist?
A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.
Find a Thyroid Specialist Near You →